Exploring the potential of BOLA3-DT as a diagnostic biomarker in prostate cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The long non-coding RNA BOLA3-DT is downregulated in prostate cancer and shows potential as a diagnostic biomarker. Its expression correlates with serum PSA levels, aiding in prostate cancer detection.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Prostate cancer (PCa) diagnosis and prognosis require reliable biomarkers.
- Long non-coding RNAs (lncRNAs) are emerging as critical regulators in cancer development.
- BOLA3-DT's role as a diagnostic marker in PCa remains to be fully elucidated.
Purpose Of The Study
- To investigate the expression profile of the lncRNA BOLA3-DT in prostate cancer.
- To evaluate the association between BOLA3-DT expression and clinicopathological parameters in PCa.
- To determine the diagnostic potential of BOLA3-DT in prostate cancer.
Main Methods
- Analysis of BOLA3-DT expression in normal versus tumor prostate tissues using the GDC TCGA PRAD dataset.
- Correlation analysis of BOLA3-DT expression with serum PSA levels and Gleason scores.
- Validation of BOLA3-DT expression in a cohort of PCa and benign prostatic hyperplasia (BPH) patients.
Main Results
- BOLA3-DT was significantly downregulated in PCa tissues compared to normal tissues (p < 0.0001).
- A significant negative correlation was observed between BOLA3-DT expression and serum PSA levels (p < 0.01).
- BOLA3-DT demonstrated high diagnostic accuracy with 86.9% sensitivity and 84.6% specificity (AUC=0.916).
Conclusions
- The lncRNA BOLA3-DT is downregulated in prostate cancer.
- BOLA3-DT expression serves as a potential diagnostic biomarker for prostate cancer.
- BOLA3-DT's diagnostic utility is supported by its performance in distinguishing PCa from normal tissues.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.